Previous 10 | Next 10 |
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 1, 2022 – Young adults are using more hallucinogens than ever. According to a National Institute of Health survey, the amount of people between age 19 to 30 who repor...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perce...
To talk about company resilience in the psychedelics industry is a bit premature. After all, most of the more prominent companies didn’t open their doors until 2016 or later. But it’s the perfect time to build a foundation for resilience while they look to a future o...
What some thought could have been the start of a meme stock rally for MindMed ( NASDAQ: MNMD ) appears to have ended, just one day after it began. After closing up 36% on Thursday, the psychedelic drug treatment company is flat in Friday morning trading. In Thursda...
MindMed, which is up 71% in Thursday premarket trading, appears to be the latest beneficiary of the meme stock craze. The company, which is developing psychedelic drug treatments, closed up 10% Wednesday. A recent story in the Financial Times about US college s...
Atai Life Sciences N.V. (ATAI) Q2 2022 Earnings Conference Call August 15, 2022 8:30 AM ET Company Participants Greg Weaver – Chief Financial Officer Stephen Bardin – Deputy Chief Financial Officer Florian Brand – Chief Executive Officer ...
Atai Life Sciences (NASDAQ: ATAI) announced fiscal second-quarter results today for the quarter ending June 30, 2022 with no revenue, but an update on expenses and cash levels. Atai completed a company-wide cost optimization initiative and an extensive pipeline revie...
ATAI Life Sciences press release ( NASDAQ: ATAI ): Q2 GAAP EPS of -$0.24 misses by $0.01 . Cash, cash equivalents and short-term investments totaled $312.5 million as of June 30, 2022, compared to $362.3 million as of December 31, 2021. For further details see: ...
- Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai’s development programs with anticipated meaningful near-term clinical value inflections -...
- Non-dilutive financing facility, plus $312M existing cash on hand as of June 30, 2022, gives atai access to up to $487M to continue developing next generation mental health treatments - Flexible draw availability provides optionality to optimize liquidity and capital struc...
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
ATAI Life Sciences N.V. Website:
Alcohol use disorder is a disorder characterized by an inability to stop or control one’s drinking despite adverse health, occupational or social consequences. Conventional treatments include medication, behavioral therapy, and support groups. Even with these treatments, however, many ind...
Psychedelics such as DMT, LSD and psilocybin have demonstrated promise in the treatment of affective symptoms of a range of disorders. These drugs work by inducing an altered state of consciousness , which includes intensified perceptions and emotions, which have been associated with therapeutic...